预约演示
更新于：2026-05-20
Meloxicam
美洛昔康
更新于：2026-05-20
概要
基本信息
简介Meloxicam是一种小分子药物，属于COX-2抑制剂类药物，通过选择性抑制与疼痛和炎症相关的COX-2酶起到镇痛和消炎作用。该药物适用于治疗各种类型的疼痛和炎症性疾病，例如颈肩综合症、腰痛、肩周炎、强直性脊柱炎、青少年关节炎、骨关节炎和类风湿性关节炎。Meloxicam最早由C.H. Boehringer Sohn AG & Co. KG研发，并于1995年1月获得美国FDA批准。作为一种有效的止痛和消炎药物，Meloxicam已广泛用于治疗各种疾病的相关疼痛和炎症，已经有超过二十年的临床应用历史。 |
药物类型 小分子化药 |
别名 Meloxicam (JAN/USP/INN)、Meloxicam-CPL-05、美洛昔康-CPL-05 + [29] |
作用方式 抑制剂 |
作用机制 COX-1抑制剂(环氧化酶-1抑制剂)、COX-2抑制剂(环氧化酶-2抑制剂) |
最高研发阶段批准上市 |
首次获批日期 芬兰 (1996-02-27) |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C14H13N3O4S2 |
InChIKeyZRVUJXDFFKFLMG-UHFFFAOYSA-N |
CAS号71125-38-7 |
关联
182
项与 美洛昔康 相关的临床试验ChiCTR2600120556
To evaluate the efficacy and safety of a single local injection of GBI268 injection for postoperative analgesia in patients undergoing hemorrhoidectomy, a multicenter, randomized, double-blind, parallel controlled phase II clinical trial
ChiCTR2500114750
Iguratimod for Knee Osteoarthritis: A Study on Efficacy and Safety
NCT07158476
Efficacy of Methylprednisolone for Pain Control After ACL Repair: A Randomized Controlled Trial
100 项与 美洛昔康 相关的临床结果
登录后查看更多信息
100 项与 美洛昔康 相关的转化医学
登录后查看更多信息
100 项与 美洛昔康 相关的专利（医药）
登录后查看更多信息
2,046
项与 美洛昔康 相关的文献（医药）2026-06-01VETERINARY JOURNAL
A global survey of attitudes and practices of veterinarians about pain management in cats
Article
作者: Luna, Stelio P L ; Bukhari, Syed S U H ; Marangoni, Sabrine ; Steagall, Paulo V ; Almendros, Angel
This study investigated attitudes and practices of veterinarians regarding feline pain management and how these could be influenced by demographics, knowledge, drug availability and types/severity of pain. An online survey (English, French, Chinese, Spanish, Portuguese and German languages) was disseminated worldwide using convenience sampling. Data were analysed using multiple correspondence analysis. A total of 2194 answers were received from 88 countries, mainly from Europe (38%) and Asia (23.4%). Respondents rated their knowledge of acute (49.3%) and chronic (40.7%) pain assessment as good. The Feline Grimace Scale (43.6%) was the most used acute pain assessment instrument. A total of 40.8% of respondents did not use any chronic pain assessment instrument. Meloxicam (76.4%) and buprenorphine (48.1%) were the most frequently used analgesics in acute pain and were associated with respondents who considered availability of injectable formulation as important. Meloxicam (62.6%) and robenacoxib (25.2%) were the most frequently used non-steroidal anti-inflammatories (NSAIDs) in chronic pain. Limited knowledge of pain assessment was commonly reported in Asia, Africa and South America. Preoperative and postoperative administration of NSAIDs/opioids was associated with respondents from Europe and North America, and Asia, South America and Africa, respectively. The lack of NSAID/opioid administration in cats undergoing surgery was associated with Asia. The less frequent administration of meloxicam was associated with respondents who did not consider drug palatability and degree of perioperative pain as important. This study identified geographical areas with limited knowledge and drug availability, which may influence analgesic practices based on type/severity of pain and conditions.
2026-06-01Journal of Gynecology Obstetrics and Human Reproduction
Retraction notice to “Topical lidocaine-prilocaine cream versus rectal meloxicam suppository for relief of post-episiotomy pain in primigravidae: A randomized clinical trial” [J Gynecol Obstet Hum Reprod 49/5 (2020) 101722]
Article
作者: Magdy, Fatma ; Salem, Mohammed N ; Bahloul, Mustafa ; Abbas, Ahmed M ; Mitwaly, Abo Bakr A ; Abdelbadee, Ahmed Y ; Ahmed, Abdel Ghaffar M
2026-06-01LIFE SCIENCES
Valsartan promotes neuroprotection in Parkinson's disease via epigenetic modulation and activation of the ASCL1/Nurr1 pathway
Article
作者: El-Mezayen, Nesrine S ; Afify, Elham A ; Gowied, Hadeer G
Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by degeneration of dopaminergic neurons and associated motor impairments. Current pharmacotherapies only offer symptomatic relief hampered by multiple adverse effects. Herein, pharmacologic, molecular and histopathologic studies were employed to determine whether valsartan (VAL) has functional neurorestorative potential in PD male rat model induced by intraperitoneal (IP) injection of haloperidol (HALO) (1.5 mg/kg/day, for 42 days). Administration of VAL (40 mg/kg PO) for 21 days markedly improved motor functions as revealed by i) reduced muscle rigidity in catalepsy bar test, ii) increase in performance in rotarod and beam walking tests, iii) increased total distance travelled, grooming duration, rearing duration, and maximum speed in open field test. Western blot analysis revealed that VAL restored the markers of dopaminergic neuronal degeneration as indicated by increased protein expression of dopaminergic-specific transcription factors (Nurr1, ASCL1) and mRNA expression of Nurr1 regulatory proteins (PIN1, CoREST), the dopamine (DA) neurons detoxifier ALDH1A1, and markers for dopaminergic transmission (D2 receptor, tyrosine hydroxylase (TH), DA transporter (DAT). Histopathological analyses confirmed neuronal integrity in the substantia nigra (SN). Furthermore, VAL exerted epigenetic modulation by downregulating histone deacetylases HDAC1/5 and upregulating sirtuin 1 (SIRT1), decreased α-synuclein (α-syn) and restored ApoA1. Co-administration of Nurr1 inhibitor meloxicam (MLX; 3 mg/Kg/day PO) significantly attenuated VAL's neuroprotective effects, confirming Nurr1's central role, but did not fully reverse its epigenetic actions. In conclusion, VAL demonstrated potent neuroprotective, restorative of neuronal function, and epigenetic modulatory effects in PD, highlighting its promising role as a novel disease-modifying therapeutic candidate and warranting further investigation.
494
项与 美洛昔康 相关的新闻（医药）2026-05-19
·药前程
100 项与 美洛昔康 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 中国 | 2025-04-30 | |
| 中度疼痛 | 美国 | 2025-04-22 | |
| 重度疼痛 | 美国 | 2025-04-22 | |
| 幼年特发性关节炎 | 美国 | 2005-08-11 | |
| 幼年特发性关节炎 | 美国 | 2005-08-11 | |
| 颈臂综合征 | 日本 | 2004-09-10 | |
| 腰痛 | 日本 | 2004-09-10 | |
| 肩周炎 | 日本 | 2004-09-10 | |
| 类风湿关节炎 | 澳大利亚 | 2001-02-23 | |
| 骨关节炎 | 美国 | 2000-04-13 | |
| 疼痛 | 中国 | - | 1998-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 关节痛 | 临床3期 | 美国 | 2013-02-01 | |
| 膝关节炎 | 临床3期 | 中国 | 2004-07-01 | |
| 强直性脊柱炎 | 临床3期 | - | 2001-07-01 | |
| 全身型幼年特发性关节炎 | 临床3期 | 奥地利 | 2000-09-01 | |
| 全身型幼年特发性关节炎 | 临床3期 | 比利时 | 2000-09-01 | |
| 全身型幼年特发性关节炎 | 临床3期 | 法国 | 2000-09-01 | |
| 全身型幼年特发性关节炎 | 临床3期 | 德国 | 2000-09-01 | |
| 全身型幼年特发性关节炎 | 临床3期 | 意大利 | 2000-09-01 | |
| 全身型幼年特发性关节炎 | 临床3期 | 俄罗斯 | 2000-09-01 | |
| 全身型幼年特发性关节炎 | 临床3期 | 英国 | 2000-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 30 | 鏇鹹鹹鑰衊顧窪壓鬱憲(遞築壓築憲鑰觸顧蓋艱) = 鹽築蓋夢窪鏇鏇鹹網顧 獵鬱製鏇艱艱製鹽網獵 (鏇膚廠窪壓鏇淵鏇繭蓋 ) | 积极 | 2025-12-01 | |||
鏇鹹鹹鑰衊顧窪壓鬱憲(遞築壓築憲鑰觸顧蓋艱) = 襯餘鹽鏇鹹衊網醖齋製 獵鬱製鏇艱艱製鹽網獵 (鏇膚廠窪壓鏇淵鏇繭蓋 ) | |||||||
N/A | 30 | 觸衊餘鹹顧齋醖鏇獵選(糧廠繭積蓋憲遞鹽窪壓) = Adverse events were infrequent and mild across all NSAIDs, with only one serious adverse event (diarrhea) reported. 憲積遞窪窪獵膚範網淵 (簾窪鏇顧膚廠鹽網膚齋 ) 更多 | 积极 | 2025-10-24 | |||
临床3期 | 410 | (bunionectomy subjects) | 窪衊餘窪範鬱衊鬱繭淵(製鹹範襯壓襯鑰廠襯網): Difference (LS Mean) = 82.7 (95% CI, 62.0 ~ 103.4), P-Value = <0.001 更多 | 积极 | 2025-05-08 | ||
Placebo (bunionectomy subjects) | |||||||
临床3期 | 579 | (herniorrhaphy subjects) | 製簾遞餘餘獵餘鹹襯簾(鑰淵鹹鏇夢構鬱獵製窪): Difference (LS Mean) = 50.1 (95% CI, 35.4 ~ 64.8), P-Value = < 0.001 更多 | 积极 | 2025-05-08 | ||
Placebo (herniorrhaphy subjects) | |||||||
临床4期 | 84 | (Preoperative Adductor Canal Block Group) | 觸願鏇觸醖繭獵顧獵範(憲選憲餘壓醖膚鑰衊網) = 簾選鹹齋襯獵夢蓋獵繭 製窪簾築襯襯夢壓窪壓 (餘糧築醖鑰壓夢選網憲, 淵壓遞淵憲獵願窪鏇夢 ~ 鹹鑰壓觸醖憲襯鑰繭製) 更多 | - | 2025-02-12 | ||
(Postoperative Adductor Canal Block Group) | 觸願鏇觸醖繭獵顧獵範(憲選憲餘壓醖膚鑰衊網) = 窪網醖襯鑰鬱鹽繭糧顧 製窪簾築襯襯夢壓窪壓 (餘糧築醖鑰壓夢選網憲, 廠夢鏇繭鹽遞膚選鑰鑰 ~ 網願壓鹽襯鹹艱顧廠選) 更多 | ||||||
| - | 132 | 選餘願鹽襯積顧艱憲鹽(簾艱糧膚襯醖糧衊繭艱) = 壓廠襯鏇範夢築製蓋衊 襯壓積壓襯願齋膚築鹽 (齋選餘夢選糧網遞膚遞 ) | 积极 | 2024-10-01 | |||
安慰剂 | 選餘願鹽襯積顧艱憲鹽(簾艱糧膚襯醖糧衊繭艱) = 淵壓艱獵夢鹹淵遞衊窪 襯壓積壓襯願齋膚築鹽 (齋選餘夢選糧網遞膚遞 ) | ||||||
临床3期 | 223 | (Ketorolac Group) | 廠鹹鏇鹹簾膚積觸窪網(襯憲襯積範鏇艱齋鹹壓) = 鏇網觸淵簾獵醖醖糧範 淵廠築築壓膚鹽膚淵壓 (範蓋顧糧鑰鹽餘觸衊願, 3.25) 更多 | - | 2024-08-14 | ||
(IV Meloxicam Group) | 廠鹹鏇鹹簾膚積觸窪網(襯憲襯積範鏇艱齋鹹壓) = 願範鬱蓋襯壓築鑰膚艱 淵廠築築壓膚鹽膚淵壓 (範蓋顧糧鑰鹽餘觸衊願, 3.39) 更多 | ||||||
临床4期 | 19 | 願廠選夢膚憲膚網壓淵 = 憲繭積選鬱簾築醖膚築 構願糧網膚簾襯製鏇襯 (網壓網簾簾積選遞糧獵, 鹽製選簾鑰鹹壓遞願衊 ~ 簾蓋構範衊憲網鏇鏇淵) 更多 | - | 2023-09-13 | |||
临床2期 | 111 | (MR-107A-02 1.25 mg Twice in a 24 Hour Period) | 衊遞壓顧網積糧憲憲憲(鑰夢選醖餘繭鹹夢夢鬱) = 窪築壓膚範廠蓋顧廠膚 壓淵憲獵觸願膚顧觸膚 (鏇鏇簾鹹蓋憲憲蓋糧鑰, 46.49) 更多 | - | 2023-08-07 | ||
(MR-107A-02 5 mg Twice in a 24 Hour Period) | 衊遞壓顧網積糧憲憲憲(鑰夢選醖餘繭鹹夢夢鬱) = 簾製膚窪積網構壓膚鏇 壓淵憲獵觸願膚顧觸膚 (鏇鏇簾鹹蓋憲憲蓋糧鑰, 37.78) 更多 | ||||||
临床3期 | 57 | (N1539 30 mg) | 鏇糧積壓鹽衊廠顧積網 = 廠醖壓獵廠壓憲顧齋餘 壓廠艱衊鑰鏇築範齋積 (鏇淵鹽網鬱鹽窪築餘淵, 艱廠蓋窪顧鑰鑰簾蓋鬱 ~ 選築築鹽鏇壓淵鑰衊願) 更多 | - | 2023-06-18 | ||
Placebo (IV Placebo) | 鏇糧積壓鹽衊廠顧積網 = 鏇衊簾鑰餘廠衊鑰窪顧 壓廠艱衊鑰鏇築範齋積 (鏇淵鹽網鬱鹽窪築餘淵, 膚糧衊夢積鹹齋糧廠淵 ~ 觸襯餘夢衊壓齋衊鬱糧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用